Amgen Inc. (NASDAQ:AMGN) Given Average Rating of “Hold” by Brokerages

Amgen Inc. (NASDAQ:AMGN) has been assigned a consensus recommendation of “Hold” from the thirty research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $355.7308.

A number of research analysts have issued reports on the company. UBS Group lifted their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Morgan Stanley dropped their target price on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a research report on Wednesday. Wells Fargo & Company lifted their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Finally, The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research note on Friday, June 5th.

Amgen Price Performance

Amgen stock opened at $363.62 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company has a market capitalization of $196.25 billion, a PE ratio of 25.30, a price-to-earnings-growth ratio of 3.63 and a beta of 0.41. Amgen has a one year low of $269.77 and a one year high of $391.29. The business has a 50 day simple moving average of $344.30 and a 200 day simple moving average of $349.22.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the previous year, the firm earned $4.90 EPS. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts forecast that Amgen will post 22.32 EPS for the current fiscal year.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Amgen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Anfield Capital Management LLC increased its stake in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC lifted its position in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in Amgen during the 4th quarter worth about $26,000. Tower View Wealth Management LLC grew its holdings in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the last quarter. Finally, Manning & Napier Advisors LLC grew its holdings in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.